The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 07, 2021
Filed:
Feb. 19, 2019
Applicant:
Immunomedics, Inc., Morris Plains, NJ (US);
Inventors:
Serengulam V. Govindan, Summit, NJ (US);
David M. Goldenberg, Mendham, NJ (US);
Assignee:
Immunomedics, Inc., Morris Plains, NJ (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 16/30 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01);
U.S. Cl.
CPC ...
C07K 16/30 (2013.01); A61K 45/06 (2013.01); A61K 47/6801 (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); A61K 47/6857 (2017.08); A61K 47/6859 (2017.08); A61K 47/6863 (2017.08); A61K 47/6865 (2017.08); A61K 47/6867 (2017.08); A61K 47/6869 (2017.08);
Abstract
The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior treatment with a checkpoint inhibitor. The therapy is effective to treat cancers that are resistant to checkpoint inhibitors.